Clinical trial
Improvement of Outcome in Elderly Patients or Patients Not Eligible for High-dose Chemotherapy With Aggressive NHL in First Relapse/Progression by Adding Nivolumab to Gemcitabine, Oxaliplatin Plus Rituximab in Case of B-cell Lymphoma
NCT03366272 is registered in ClinicalTrials.gov with Universität des Saarlandes as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Improvement of Outcome in Elderly Patients or Patients Not Eligible for High-dose Chemotherapy With Aggressive NHL in First Relapse/Progression by Adding Nivolumab to Gemcitabine, Oxaliplatin Plus Rituximab in Case of B-cell Lymphoma
- Lead sponsor
- Universität des Saarlandes
- Phase
- Phase 2/3
- Overall status
- Completed
- Start date
- December 5, 2017
- Completion date
- January 15, 2025
- Enrollment
- 348 (actual)
- Sites
- 77
Conditions
As the registry lists them; a condition with its own page is linked.